{"id":"NCT01997229","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2016-02","completion":"2016-06","firstPosted":"2013-11-28","resultsPosted":"2018-02-07","lastUpdate":"2019-07-16"},"enrollment":125,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Refractory Generalized Myasthenia Gravis"],"interventions":[{"type":"BIOLOGICAL","name":"Eculizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Eculizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.","primaryOutcome":{"measure":"Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)","timeFrame":"End of study (Week 26)","effectByArm":[{"arm":"Eculizumab","deltaMin":56.6,"sd":4.53},{"arm":"Placebo","deltaMin":68.3,"sd":4.49}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0698"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":114,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Italy","Japan","Netherlands","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["23512355","29066163","34795626","34590717","33329303","33229455","32700461","32426038","32189108","30905021"],"seeAlso":["http://www.alexionclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":62},"commonTop":["Headache","Upper respiratory tract infection","Nasopharyngitis","Nausea","Diarrhoea"]}}